We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Improved Ebola IVD Tests Continue to Face Challenges

By LabMedica International staff writers
Posted on 13 Apr 2015
A new Ebolavirus test provides significant advantage over the current diagnostic pathway, yet there is little justification to establish permanent, advanced testing at expense of more pressing needs. More...


The new Ebolavirus test, Improved Ebola Diagnostic, developed by the UK’s Defence and Science Technology Laboratory (DSTL) is a step forward and provides significant advantage as it can be carried out at point-of-care (POC) and uses a much smaller sample of capillary blood. However, there remains a need for low-cost, POC testing devices that overcome the logistical and geopolitical obstacles presented by Sub-Saharan Africa, according to Andrew S. Thompson, PhD, senior analyst covering in vitro diagnostics (IVD) at research and consulting firm GlobalData (London, UK).

“By performing the test at the patient’s bedside, the risks of exposure, through transport to a laboratory, are minimized. It needs no specialist equipment and requires very little training, which reduces the diagnostic load on the pathology laboratory, freeing up capacity for confirmatory testing,” said Mr. Thompson.

“However, while the test was shown to be very successful in diagnosing patients admitted to hospital, and who were therefore symptomatic for Ebola, no such testing was carried out on asymptomatic patients in a non-hospital setting.” Furthermore, because viruses such as Ebola generally result in transient outbreaks in poverty-stricken regions, there is little justification to establish permanent, high-grade, molecular diagnostic testing if it comes at cost to more pressing and basic healthcare needs.

“The present Ebola outbreak is the largest known in history, but it is difficult to predict, once it subsides, if such repeated large-scale casualty events will occur again. In any case, Ebola is just one of many emerging, highly pathogenic viruses affecting Sub-Saharan Africa,” said Mr. Thompson, “For now, new tests such as DSTL’s Ebola lateral flow assay, based on long-established and mature technology, remain the best point-of-care testing for rare and emerging infectious diseases. However, in the longer term, these are likely to be overtaken by miniaturized nucleic acid-detection platforms, which can truly bring the gold standard of testing out of the laboratory.”

Related Links:

GlobalData



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The automated multiplex PCR assay runs on the BioFire Spotfire Vaginitis System, bringing molecular vaginitis testing to the point of care (Photo courtesy of bioMérieux)

Molecular Vaginitis Panel Gains FDA Clearance and CLIA Waiver for Point-of-Care Use

Vaginitis affects most women at least once in their lifetime and can cause painful, disruptive symptoms. Common causes include bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis, reflecting... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: The CE-marked software IVD combines digital histopathology and clinicopathological data to generate a prognostic classification (Image Credit: Shutterstock)

Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer

In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The integration with FlexLab X brings the Panther System into fully tracked automation environments to increase capacity, traceability, and workflow efficiency (Photo courtesy of Hologic)

Hologic and Inpeco Partner to Advance Molecular Laboratory Automation in Europe

Hologic, Inc. (Marlborough, MA, USA) and Inpeco S.A. (Novazzano, Switzerland) have signed a co-marketing partnership in Europe for Inpeco’s recently launched FlexLab X automation solution and Hologic’s... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.